Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17115832 | 0.83 | CYP2D6 (0.43) | CYP2D6ADRA2AADRA1ACHRM2CHRM1 | |
| SCHEMBL7937557 | 0.82 | CYP2D6 (0.46) | CYP2D6ADRA2AADRA1ACHRM2CHRM1 | |
| SCHEMBL11143567 | 0.81 | CYP2D6 (0.44) | CYP2D6ADRA2AADRA1AMEN1KMT2A | |
| SCHEMBL2701413 | 0.80 | CYP2D6 (0.41) | CYP2D6ADRA2AADRA1ACHRM2CHRM1 | |
| SCHEMBL20256745 | 0.80 | ADRA2A (0.46) | CYP2D6ADRA2AADRA1ACHRM2CHRM1 | |
| SCHEMBL16960809 | 0.78 | CYP2D6 (0.43) | CYP2D6ADRA2AADRA1ACHRM2CHRM1 | |
| SCHEMBL31119047 | 0.78 | ADRA2A (0.49) | CYP2D6ADRA2AADRA1AMEN1KMT2A | |
| SCHEMBL2823287 | 0.78 | CYP2D6 (0.53) | CYP2D6ADRA2AADRA1ACHRM2CHRM1 | |
| SCHEMBL3702003 | 0.78 | CYP2D6 (0.53) | CYP2D6ADRA2AADRA1ACHRM2CHRM1 | |
| SCHEMBL31119095 | 0.78 | CYP2D6 (0.43) | CYP2D6ADRA2AADRA1ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012041014-A1 | TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-7115766-B2 | Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORP. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040034246-A1 | Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-19 | — | — | US | disclosed |
| WO-2002044144-A2 | NUCLEOPHILIC APPROACH FOR PREPARING RADIOLABELED IMAGING AGENTS AND ASSOCIATED COMPOUNDS | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034246-A1 | Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds | SNCA, PARK7, SAMHD1 | CYP2D6 3449/4885ADRA2A 2471/4885ADRA1A 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.